Elche

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in … Ended recruitment
  2023-505812-39-00 5 2020-08-28 HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral trea … Ended recruitment
  2024-511940-20-00 5 2020-02-05 Parkinson's disease
• Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiation Ended recruitment
  2023-510268-11-00 4 2019-06-11 Cervical cancer
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Study of Zolbetuximab (IMAB362) plus CAPOX in Adults with Gastric Cancer. Ended recruitment
  2024-511648-16-00 5 2019-01-04 Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresecta
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi … Ended recruitment
  2024-510967-41-00 5 2018-09-21 Metastatic colorectal cancer
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Ended recruitment
  2023-505341-23-00 5 2018-07-27 Non-muscle invasive bladder cancer
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Pilot study to explore the diagnostic value of gadopiclenol in pathological and radiological insights with multiparametric MRI enhancement i … Ended
  2025-521810-24-00 6 2025-09-22 Breast cancer
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• PH2a, VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living with HIV-1 Ended
  2023-507173-18-00 4 2024-04-09 HIV Infections
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Ended
  2023-509095-42-00 4 2022-07-14 Colorectal cancer
• Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2 Ended
  2024-519691-10-00 6 2022-05-27 Septic Shock
• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
• Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progress … Ended
  2024-518875-73-00 5 2021-12-10 Huntington Disease
• DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial Ended
  2024-515167-56-00 11 2021-06-22 HIV
• Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c … Ended
  2024-514803-33-00 4 2021-06-16 Non-small cell lung cancer (NSCLC)
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 5 2021-05-27 Parkinson's disease
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc

Showing 97–120 of 126 trials